Recently, a phase I clinical study of lifirafenib (BGB-283), a RAF family kinase inhibitor, showed patients with KRAS-mutated endometrial cancer and NSCLC had a confirmed PR (n = 1 each), while no response was observed in patients with KRAS- or NRAS-mutated colorectal cancer (n = 20) [131]. Here, KRAS is linked to colorectal cancer.